---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042277"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:30:04.499595+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma CDO resigns; CMO and VP Clinical Dev to assume duties

## Summary
- Chief Development Officer Theresa Matkovits resigned effective October 23, 2024, to pursue another opportunity.
- Resignation not due to material disagreement or change in company direction.
- James J. Ferguson (CMO) and Susan Johansson (VP Clinical Dev) will fill her responsibilities.
- Company continues to work toward partnership on MAT2203, its oral amphotericin B formulation.

## SEC filing metadata
- accession: 0001493152-24-042277
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224042277/0001493152-24-042277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224042277/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042277
- JSON: https://secwatch.observer/filing/0001493152-24-042277.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.